The Cancer Letter

Inside information on cancer research and drug development

In Brief

Jill DeSimone joins Swim Across America’s board of directors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Jill DeSimone, a global pharmaceutical executive, joined Swim Across America’s board of directors. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
In Brief

CPRIT awards $67M in research grants to Texas institutions

The governing body of the Cancer Prevention and Research Institute of Texas approved 53 grants totaling more than $67 million to state research institutions to advance the state’s fight against cancer. The grants provide funding for a wide array of cancer projects, including CPRIT Scholar recruitment awards, funding for collaborative core facilities, and support for cancer clinical trials.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account